LONDON, Dec 7 (Reuters) – Bristol-Myers Squibb’s
immunotherapy drug Opdivo has been approved in Europe for the
treatment of classical Hodgkin lymphoma, a rare blood cancer,
the U.S. company said on…
The post EU clears Bristol-Myers immunotherapy drug for blood cancer appeared first on NASDAQ.